HYBIO(SZ:300199)2023-10-13 09:38Group 1: Internationalization Strategy - The company has focused on the internationalization strategy for over 20 years, specializing in peptide drugs [1][2] - It successfully signed a large order worth 219 million CNY for GLP-1 peptide raw materials in September, with production and delivery already in progress [2] - A global promotion agreement covering 78 countries has been established with Ferring Pharma for peptide drugs [2] Group 2: Product Pipeline and Regulatory Approvals - The company has multiple peptide drugs and formulations that have been approved in international markets, including the FDA approval for the peptide injection Exenatide and the EU approval for Atosiban [2] - The company is actively advancing the development and registration of GLP-1 peptide formulations, with the FDA review for a major GLP-1 formulation currently in its final stages [2] - The company has received clinical trial approval for Semaglutide from the National Medical Products Administration in China [2] Group 3: New Product Development - In addition to pharmaceutical products, the company is expanding into new retail peptide products, including weight loss peptides, sleep aid peptides, and uric acid-lowering peptides [3]